Managing BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Clinical and Operational Perspectives : Episode 2
Opinion
Video
Challenges of BCG-Unresponsive NMIBC
Author(s):
Key Takeaways
- BCG therapy resistance in bladder cancer patients is influenced by tumor biology, immune variability, and genetic factors, impacting prognosis negatively.
- Non-responders to BCG therapy often require alternative treatments, facing a poorer prognosis compared to responders.
Katie S. Murray, DO, discusses why some patients do not respond to BCG therapy, exploring factors such as tumor biology and immune system dysfunction, and how this impacts their prognosis, while also addressing the challenges and unmet needs in treating these patients, including the current BCG shortages and how it is reshaping treatment approaches.
Video Player is loading.
- Why do some patients not respond to BCG therapy and how may it impact their prognosis?
- What challenges or unmet needs do you face when treating these patients?
- Discuss your thoughts and opinions on the current BCG shortages. How is this changing how you are managing your patients?
Related Videos
Future Directions of BCG-Unresponsive NMIBC Management
Adoption of New Treatments for BCG-Unresponsive NMIBC
Navigating Treatment Choices and Financial Considerations in BCG-Unresponsive NMIBC
BCG-Unresponsive NMIBC: Balancing Care and Financial Considerations
The Impact of Gene Therapy and Advancements in BCG-Unresponsive NMIBC Treatment
Navigating BCG-Unresponsive NMIBC and Emerging Therapies
Enhancing Access to BCG-Unresponsive NMIBC Treatments
Reducing Resource Expenditure in Clinics with New Gene Therapies for BCG-Unresponsive NMIBC
Cost-Effectiveness and Patient Support in Treating BCG-Unresponsive NMIBC
Discussing Treatment Options for BCG-Unresponsive NMIBC
Related Content
